Humax CD-20

[Guest guest]

The following comes from an announcement by the manufacturer of

Humax CD-20, foretelling the content of its ASH presentation. Does

anyone have a link to the ASH abstract? I was particularly

interested in the following announcement, as dreaded DLBCL

transformation cells were quite susceptible to Humax. It is my

understanding that Richter's is somewhat similar to DLBCL. It would

surely warm the hearts of many if it were determined through human

studies that Humax CD-20 might add punch to DLBCL as well as

Richter's treatments.

Warm wishes,

Jan

Ofatumumab data

In a pre-clinical study, ofatumumab appeared to be more effective

than rituximab in treating chemotherapy refractory diffuse large B-

cell lymphoma (DLBCL). Ofatumumab was significantly more effective

in inducing the immune system killing mechanism complement dependent

cytotoxicity (CDC) in 9 of 10 DLBCL tumor samples when compared to

rituximab. In addition, the dose of ofatumumab required to kill the

patients' tumor cells was lower than that required for rituximab.

In an additional pre-clinical study, B-cells incubated with

cholesterol depleting agents called statins were found to be killed

less effectively by CD20 monoclonal antibodies. Importantly, cell

lysis of statin-treated B-cells was consistently higher when using

ofatumumab in comparison to rituximab. Statin incubation was shown

to induce conformational changes in the CD20 target and impaired the

binding of ofatumumab and rituximab to the CD20 molecule.

Previously reported data illustrating that ofatumumab appears to

induce CDC of target cells far more rapidly and effectively than

rituximab will also be presented at the ASH conference.

[Guest guest]

Also active in CLL - in a high-risk group:

Ofatumumab (HuMax-CD20), a Novel CD20 Monoclonal Antibody, Is An

Active Treatment for Patients with CLL Refractory to Both Fludarabine

and Alemtuzumab or Bulky Fludarabine-Refractory Disease: Results from

the Planned Interim Analysis of An International Pivotal Trial

Monday, December 8, 2008: 11:45 AM

http://ash.confex.com/ash/2008/webprogram/Paper5918.htm l

n = 138 previously treated CLL patients (Double refractory, n=59;

Bulky fludarabine refractory, n=79

>

> The following comes from an announcement by the manufacturer of

> Humax CD-20, foretelling the content of its ASH presentation. Does

> anyone have a link to the ASH abstract? I was particularly

> interested in the following announcement, as dreaded DLBCL

> transformation cells were quite susceptible to Humax. It is my

> understanding that Richter's is somewhat similar to DLBCL. It

would

> surely warm the hearts of many if it were determined through human

> studies that Humax CD-20 might add punch to DLBCL as well as

> Richter's treatments.

>

> Warm wishes,

>

> Jan

>

> Ofatumumab data

>

> In a pre-clinical study, ofatumumab appeared to be more effective

> than rituximab in treating chemotherapy refractory diffuse large B-

> cell lymphoma (DLBCL). Ofatumumab was significantly more effective

> in inducing the immune system killing mechanism complement

dependent

> cytotoxicity (CDC) in 9 of 10 DLBCL tumor samples when compared to

> rituximab. In addition, the dose of ofatumumab required to kill

the

> patients' tumor cells was lower than that required for rituximab.

>

>

>

> In an additional pre-clinical study, B-cells incubated with

> cholesterol depleting agents called statins were found to be killed

> less effectively by CD20 monoclonal antibodies. Importantly, cell

> lysis of statin-treated B-cells was consistently higher when using

> ofatumumab in comparison to rituximab. Statin incubation was shown

> to induce conformational changes in the CD20 target and impaired

the

> binding of ofatumumab and rituximab to the CD20 molecule.

> Previously reported data illustrating that ofatumumab appears to

> induce CDC of target cells far more rapidly and effectively than

> rituximab will also be presented at the ASH conference.

>

[Guest guest]

Rcihter's is usually referred to as a transformation from CLL to DLBCL

**************One site keeps you connected to all your email: AOL Mail, Gmail, and Mail. The NEW AOL.com.(http://www.aol.com/?optin=new-dp&icid=aolcom40vanity&ncid=emlcntaolcom00000019)

[Guest guest]

Thank you, . I had wondered about that. I thought I had once read that

that is so but just couldn't remember for sure. But actually, though I didn't

make it clear at all in my previous letter, I was assuming (probably wrongly)

that it was fNHL transformation that the paper was referring to.

Warm wishes,

Jan